Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis

Preliminary clinical data presented at the InSiGHT Biennial Meeting demonstrate significant reductions in duodenal polyposis and the size of the co-existing desmoid tumor in a patient from the ongoing Phase 1/2 trial of zolucatetide CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a